Trial Profile
An Open-Label, Single-Arm, Phase I Study to Evaluate the Effect of Ofatumumab on Cardiac Repolarization (QTc Duration) in Patients With Fludarabine-Refractory B-cell Chronic Lymphocytic Leukemia.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 11 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
- 26 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.